sel. reversible cov. immunoproteosome inh.
oral efficacy (1 mpk) in xeno., Ph. I in MM
Mol. Cancer Ther., May 27, 2021
Merck KGaA, Darmstadt, DE
The Merck LMP7 inhibitor, M3258, is an orally available, selective, and reversible inhibitor of the immunoproteasome proteolytic subunit, LMP7. In contrast to the constitutive proteasome, the immunoproteasome is predominantly expressed…